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Background: Purchase of short-acting b2-agonist (SABA), but not anti-inflammatory asthma
medication, is permitted in Australia without a doctor’s prescription. This has been associated
with worse asthma outcomes. We sought to compare the asthma outcomes between those
purchasing SABA with and without a doctor’s prescription.
Methods: Design: Cross-sectional study, using stratified randomisation of pharmacies. Setting:
43 pharmacies in Victoria, Australia.
Participants: Up to 10 consecutive adults purchasing b2-agonists were recruited from each
pharmacy, with 316 adults in total.9076 3836; fax: þ61 03 9076 2245.
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224 J.A. Douglass et al.Outcome measures: Participants underwent spirometry and questionnaires on respiratory
health, asthma control, Quality of Life and medication adherence. Asthma severity was deter-
mined by GINA medication step. Regression analyses were performed that allowed for clus-
tering by pharmacy.
Results: Of 316 individuals recruited (65% participation rate), 191 (60%) purchased a b2-agonist
with a prescription. Purchase of SABA without prescription was not associated with worse
asthma outcomes or lung function. Mean (SD) asthma control score (ACQ) was 1.65  1.03;
only 63 (20%) had well-controlled asthma (ACQ < 0.75). Anti-inflammatory asthma medication
was owned by 188 (60%) of participants, of whom 157 (83%) reported using this in the last 7
days. There was no correlation between medication adherence scores and asthma control.
Forty-seven participants (15%) had an FEV1 below 80% predicted and did not own an anti-
inflammatory asthma medication.
Conclusion: Purchase of SABA without prescription was not associated with worse asthma
outcomes in Australia. Although many patients reported symptoms of asthma, this did not
appear to be associated with reported adherence to anti-inflammatory asthma medication.
ª 2011 Elsevier Ltd. All rights reserved.Background
Australia is unique amongst nations with universal health
care systems in permitting the sale of short-acting b2-
agonists (SABA) for the treatment of asthma from phar-
macies without a doctor’s prescription (“over-the-
counter”). In contrast, anti-inflammatory asthma medica-
tions such as inhaled corticosteroids (ICS), long-acting b2-
agonists (LABA) and their combinations can only be ob-
tained by means of a doctor’s prescription, with the
purchase price heavily subsidised by the government.
Provision of SABA without prescription has been associ-
ated with sub-optimal asthma care and poor symptom con-
trol.1e6 Individuals who purchased SABA without a doctor’s
prescription were more likely to have under-treated asthma
and consult doctors less frequently.2 High levels of asthma
symptoms were described3 and qualitative evidence sug-
gested that purchase of SABA without a prescription was
partly to avoid regular medical review.5 Over-the-counter
purchase of SABA medication has been controversial within
Australia, with concerns that ready availability of SABA
without oversight of a medical practitioner may result in
SABA overuse and associated risks of sub-optimal asthma
control.7 In contrast, it might be expected that people with
asthma would welcome the availability of SABA without
a prescription, especially if there was no difference in cost.
The various studies examining SABA purchase without
a prescription were performed prior to major asthma public
health initiatives which have taken place over the past two
decades and prior to the introduction of combination LABA
and ICS inhalers. However, while asthma mortality rates in
Australia and other countries with similar public health
systems, such as the UK, have fallen, asthma mortality and
morbidity remain a significant public health concern.8
Furthermore, recent studies suggest that asthma is
commonly poorly controlled with high levels of symp-
toms.9,10 Poor asthma control is usually attributed to
inadequate use of asthma preventer medication.9 Tele-
phone survey data show that only 41% of Australians with
daily asthma symptoms were taking inhaled corticosteroids,
suggesting that a significant proportion of people with
asthma are under-medicated with preventers.10 In thiscontext, the requirement of a prescription for SABA argu-
ably provides an important opportunity for assessment of
asthma control and the concurrent prescription of
preventer medication.
In order to investigate the contribution of the availability
of SABA without a doctor’s prescription to adverse asthma
outcomes, we studied people with asthma at the point of
purchase of SABA from community pharmacies to determine
whether there were any differences in asthma control, lung
function, medication use and adherence amongst those who
purchased SABA with or without a doctor’s prescription.
Methods
The study was approved by the Alfred Hospital Human
Research Ethics Committee and endorsed by The Pharmacy
Guild of Australia.
Participants
Pharmacies
We set out to recruit a representative sample of community
pharmacies. Pharmacies were randomly selected using
a computer generated list of 956 metropolitan and rural
pharmacies in Victoria.11 We excluded (i) hospital associ-
ated pharmacies due to their non-representativeness and
(ii) pharmacies in remote regions because of the significant
travel costs that would have been incurred for low numbers
of participants. Remoteness was based on the road distance
people have to travel to reach a range of services classified
according to the Pharmacy Access/Remoteness Index
(PhARIA).12 Sampling was stratified to ensure recruitment
of metropolitan and regional pharmacies. Invitations were
sent to 56 randomly selected pharmacies, of which 43 (77%)
agreed to participate. The researcher spent up to one week
in each pharmacy or until 10 patients were recruited,
whichever occurred first. Data collection took place on site,
between June 2004 and July 2005.
Participants
All individuals aged over of 16 years purchasing SABA
medications for their personal use were eligible to
Figure 1 Percentage of participants compared to non
participants by age. Older people were significantly less likely
to refuse to participate in the study compared to younger
age groups (p <0.001).
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pharmacist at the point of sale. Those who expressed
interest were introduced to the researcher who obtained
informed written consent. Participants completed:
1) Pre- and post-bronchodilator spirometry, performed
according to ATS criteria13 using a portable spirometer
(Microlab, MicroMedical Ltd, Rochester UK) and inter-
preted using ECSC predicted normal values14
2) The European Community Respiratory Health Survey
Questionnaire, modified to include current medication
and smoking history15
3) An Asthma-related Quality of Life questionnaire
(AQOL)16
4) The Asthma Control Questionnaire (ACQ)17
5) An assessment of adherence to asthma anti-
inflammatory medications using a 4-item Adherence
Questionnaire (ADH) previously validated in asthma18,19
and the standard question “Have you used your asthma
preventer in the past 7 days?”
There was complete ascertainment of eligible customers
presenting to the pharmacy for purchase of asthma treat-
ments. The researcher also recorded the number of eligible
customers who did not participate. Their gender and esti-
mated age-range was recorded to allow some demographic
comparison of responders and non-responders.Analysis
Sample size
The sample size was calculated to detect the minimum
clinically important difference (MCID) of 0.5 in the ACQ
between those receiving b2-agonist with or without
a doctor’s prescription. Previous reports of the mean (SD)
Asthma Control Score were 1.49  0.66 for the population
with asthma. To detect the MCID with a power of 95% and
a type 1 error rate of 0.05, assuming equal variances in the
groups, we needed to recruit a minimum of 48 participants
in each group. To allow for the effects of clustering by
pharmacy, we assumed an intra-class correlation of 0.05
resulting in a design effect of 1.45 which inflated this to 70.
Based on previous research2 we assumed that only 30% of
study participants would have a prescription for SABA which
meant we would need to recruit 280 participants.
Statistical analysis
Data were entered in SPSS (Statistical Package for Social
Sciences Version 17, Chicago, Ill: SPSS, 2008). Summary
statistics for continuous variables are presented as
mean  SD unless otherwise stated. Differences between
means were assessed with Student’s t-test or Mann-Whitney
U Test for skewed data. We used Chi-square to test
differences in proportions between categorical variables
and Spearman’s correlation to study the relationship
between ACQ and adherence scores. Linear regression
models with robust variance estimation accounting for the
effects of clustering by pharmacy were fitted to determine
the relationships between prescription use, asthma
severity, ACQ, AQOL, ADH and FEV1. As ACQ values were not
normally distributed, a square-root transformation wasapplied prior to this analysis. Similarly, AQOL scores were
log-transformed. P-values of less than 0.05 were considered
significant.
Asthma severity
In accordance with recent guidelines, we estimated asthma
severity by determining treatment according to the GINA
treatment step (GINA 1-5).20,21 Individuals purchasing their
first asthma medication (who had no medication use prior
to their index pharmacy presentation) were categorised as
“No Prior Medication”.
Results
Participants
Of 479 eligible individuals, 316 (66%) participated in the study.
Younger people were less likely to participate (see Fig. 1).
The demographics of participants are listed in Table 1. A
previous doctor-diagnosis of asthma was reported by 295.
There were 126 (40%) life-long non-smokers, 83 (26%)
current smokers and 107 former smokers. Of the former and
current smokers, 25% (80) had less than a 10 pack-year smoking
historywhile 35% (110) had a greater than 10pack-year history.
Purchase of SABA without a prescription
SABA medication was purchased without a prescription by
125 (39.6%), while 191 (60.4%) had a doctor’s prescription.
Simple between-group comparisons of lung function, ACQ,
AQOL and ADH scores are presented in Table 2, revealing
that purchase with a prescription appeared to be associ-
ated with worse asthma control, asthma related quality of
life and lung function.
Further analysis was conducted to ascertain the major
associations with ACQ and to correct for asthma severity,
Health Care Card ownership and the effects of clustering by
pharmacy (Table 3). This analysis revealed no significant
differences in asthma control between those who
purchased SABA with or without prescription. The major
factor determining the ACQ score was asthma severity as
determined by GINA medication step. Health Care Card
ownership was also associated with a small but significant
increase in the ACQ score, indicating worse asthma control.
Table 1 Participant demographics. There were 316 study
participants. Adherence scores were only determined in
those taking regular inhaled preventer medication (n=188).
Four participants did not provide sufficient information for
inclusion in the calculation of medication step. Sixteen
participants claimed that their anti-inflammatory medica-
tion was “as needed” and were therefore classified as
Step 1.
Age (years) Mean  SD 46.7  19 yrs
Female 173 (55%)
Mean (SD) FEV1 maximum
post-bronchodilator (L)
2.41  0.97
Mean (SD) Asthma Control
Score (<0.75 well controlled,
>1.5 uncontrolled)
1.65  1.03
Mean (SD) Asthma-related
Quality of Life
0.86  0.74
Mean (SD) Adherence Score 2.04  1.6
Health Care Card Owners 160 (50.6%)
Classification of Severitya
No prior diagnosis 11 (3.5%)
GINA step 1 129 (41.3%)
GINA step 2 24 (7.7%)
GINA step 3 45 (14.4%)
GINA step 4 88 (28.2%)
GINA step 5 15 (4.8%)
Missing data 4
a Asthma severity was classified by the GINA treatment step.21
226 J.A. Douglass et al.Similarly, the major determinant of QOL was asthma
severity categorised by GINA treatment step, rather than
purchase of medication with a prescription (data not
shown).
Reliever use
Only 76 participants (24%) used no SABA medication on most
days, 102 (32%) used 1 to 2 puffs most days, and 59 (19%)
used 3 to 4 puffs most days. The remaining 78 participants
(25%) used 5 or more puffs on most days.Table 2 Lung function, Asthma-related Quality of Life and A
purchase of SABA with and without a prescription. Comparisons w
Mann-Whitney test (MW) if the data were skewed.
Mode of reliever purchase Prescription
(n Z 191)
Age (years) Mean  SD 53.6  19.4
FEV1% predicted Mean  SD 78.7  24.8
FEV1 pre-bronchodilator Mean  SD 2.16  0.95
Change in FEV1 (%) 4.42  9.2
% on controller medications 65% (n Z 126)
AQOL median (25%, 75%) 0.71 (0.32, 1.42)
Asthma Control Score
median (25%, 75%)
1.57 (0.86, 2.57)
Adherence Score
(4 item) median (25%, 75%)
2.00 (0.00, 3.00)
Abbreviations: SD Z Standard Deviation.Anti-inflammatory asthma medication use, asthma
control and quality of life
Ownership of asthma preventer (anti-inflammatory)
medication was high with 60% (188) having an asthma
preventer. Of these, 114 (61%) used a salmeterol/flutica-
sone combination, while an eformoterol/budesonide
combination was used by 18 (10%). The remainder used
inhaled corticosteroids without a LABA, or nedocromil.
After converting the prescribed corticosteroid dose to
beclomethasone equivalents, the median dose of inhaled
corticosteroids per day was 500 (IQR 400-1000 mcg) for the
group as a whole.
In accordance with convention, we considered an ACQ
score of <0.75 as well controlled, between 0.75 and 1.5 as
partly controlled and >1.5 as uncontrolled. Asthma was
rated as well controlled in 63 (20%), partly controlled in 85
(27%) and uncontrolled in 131 (42%), with 3 missing data. In
the group with uncontrolled asthma, 47 (36%) did not have
anti-inflammatory asthma medication. A further 34 partic-
ipants had fixed irreversible airflow obstruction on
spirometry (FEV1< 70% predicted) and a greater than 10
pack-year smoking history. We classified this group as
having a more correct diagnosis of COPD and their ACQ was
correspondingly poor (2.4  0.83) and were not included in
this comparison.
Adherence to asthma medications
All participants were asked if they had taken their anti-
inflammatory asthma medication in the past 7 days. Of
the 188 (61%) of individuals who had such medication, 157
(83%) claimed to have used it in the past 7 days. Simple
comparison showed that individuals who purchased their
SABA with a prescription were more likely to have used
preventer medication in the past 7 days (Chi-squared
5.06, p Z 0.02). We further assessed adherence to
asthma anti-inflammatory medication in those partici-
pants who owned an asthma preventer medication using
a 4-item questionnaire (ADH)18,19 where a lower score
indicated better medication adherence (Table 1). We
found no significant correlation between the asthma
control score and ADH for controller/preventersthma Symptom Control for study participants according to
ere made by t-test if the data were normally distributed or
Without prescription
(n Z 125)
p-value Missing
data (n)
38.7  13.6 <0.001 0
83.6  21.1 0.07 3
2.79  0.86 <0.001 3
6.74  9.5 0.034 7
50% (n Z 62) 0.003 6
0.54 (0.33, 0.92) 0.018 2
1.43 (0.86, 1.93) 0.027 3
3.00 (2.00, 4.00) <0.001 137
Table 3 Asthma control by purchase with and without script, by gender, Health Care Card ownership and GINA medication
step level. Parameters and estimated marginal means for the Asthma Control Questionnaire using a linear regression analysis to
account for the effects of clustering by pharmacy. This shows that asthma severity by GINA step was the major determinant of
Asthma Control score rather than purchase with or without a prescription. Health Care Card holders also had a poorer Asthma
Control score likely indicative of lower socioeconomic status and age.
Marginal Means Parameter Estimates
Mean Asthma
Control Score
95% CI
Lower
95% CI
Upper
Regression
coefficient
95% Confidence
Interval
p-value
Lower Upper
All participants 1.67 1.52 1.83
Purchase of b2-agonist
with prescription
1.69 1.47 1.92 0.01 0.110 0.131 0.9
Purchase of b2-agonist
without prescription
1.66 1.45 1.89
Gender: Female 1.61 1.41 1.82 0.053 0.132 0.026 0.2
Gender: Male 1.74 1.58 1.91
Health Care Card holder 1.84 1.62 2.07 0.0560 0.016 0.236 0.02
Non-Health Care Card holder 1.52 1.33 1.72
Asthma Severity
Medication Step
No Prior Medication 1.58 1.06 2.21 0.474 0.755 0.194 0.001
GINA step 1 1.20 1.03 1.38 0.638 0.827 0.449 0.001
GINA step 2 1.41 1.09 1.77 0.544 0.790 0.298 <0.001
GINA step 3 1.40 1.15 1.67 0.549 0.775 0.324 <0.001
GINA step 4 1.73 1.52 1.95 0.417 0.608 0.227 <0.001
GINA step 5 3.00 2.40 3.66
Over-the-counter b2-agonist purchase versus script 227medication use (Spearman’s rho Z 0.048, p Z 0.6). We
further examined this relationship using linear regression
and showed that purchase of SABA with a prescription,
gender, ownership of a Health Care Card and asthma
severity were not associated with adherence scores.
However increasing age was associated with improved
adherence scores (Table 4).Table 4 Adherence by purchase with and without script, gender
Parameters and estimated marginal means for Adherence Score
cation using linear regression analysis to account for the effects o
Adherence score. There was no association between asthma seve
Marginal Means
Mean Adherence
Score
All participants 0.29
Age
Purchase of b2-agonist
with prescription
0.25
Purchase of b2-agonist
without prescription
0.34
Gender: Female 0.29
Gender: Male 0.29
Health Care Card holder 0.25
Non-Health Care Card holder 0.33
Asthma Severity Medication
Step
GINA step 1 0.28
GINA step 2 0.28
GINA step 3 0.45
GINA step 4 0.40
GINA step 5 0.11Abnormal lung function
Almost half of the participants (141 or 45%) had impaired
lung function with an FEV1 less than 80% predicted. Fifty
(34.7%) of these purchased their SABA without a doctor’s
prescription. Linear regression analysis allowing for the
effects of clustering by pharmacy of post-bronchodilator
FEV1 confirmed that purchase of SABA without, Health Care Card ownership and GINA medication step level.
(ADH) in the 188 participants who owned a preventer medi-
f clustering by pharmacy. Age was a predictor of improved 30
rity and adherence score.
Parameter Estimates
95% CI
Lower
95%
CI Upper
Regression
coefficient
95% Confidence
Interval
p-value
Lower Upper
0.17 0.41
0.969 0.950 0.989 0.003
0.12 0.37 0.65 0.284 1.478 0.3
0.17 0.50
0.12 0.46 0.985 0.401 2.422 0.9
0.17 0.41
0.14 0.37 0.694 0.360 1.339 0.3
0.17 0.48
0.00 0.57 3.104 0.424 22.721 0.3
0.07 0.49 3.055 0.262 35.672 0.4
0.32 0.59 6.531 0.805 52.964 0.08
0.27 0.54 5.337 0.637 44.693 0.1
0.09 0.32 1.0
228 J.A. Douglass et al.a prescription was not associated with worse lung function
(B Z 0.014; 95% CI -0.133e0.160). Again, asthma severity
was strongly associated with reduced lung function
(p < 0.001). Of those with impaired lung function 47 (15%)
did not own preventer medication.Discussion
In this sample of 316 people with asthma recruited from
randomly selected community pharmacies in Victoria,
purchase of SABA medication without a doctor’s prescrip-
tion was not associated with worse asthma outcomes. This
contrasts with a number of previous reports1e6 and suggests
that the current environment of asthma care within Aus-
tralia ensures good access to anti-inflammatory asthma
medication despite the ready availability of SABA without
a medical prescription. The similarity of asthma treatment
guidelines in nations with comparable health care systems,
such as Canada and the UK,22,23 adds further support to the
generalisability of our findings which have substantial
implications for the provision of accessible asthma care.
Several reasons may account for this finding. In this study,
asthma preventer ownership was high compared to previous
reports, with 60% of individuals stating they owned an asthma
preventer inhaler, of whom 83% claimed to have used it in the
past 7 days. In a selected sample of middle-aged patients
from Tasmania, Kandane-Rathnayake and colleagues re-
ported that 78% of participants with asthma used SABA of
which 43% also reported using an asthma preventer, indi-
cating that 55% of this group owned asthma preventer
medication.24 This is comparable to our findings where the
method of recruitment ensured that all participants owned
a SABA, of whom 60% also owned a preventer. However, these
findings differ greatly from a telephone survey of people over
the age of 5 years recruited from the community which
showed that only 28% of those reporting SABA medication use
in the past two weeks also used inhaled corticosteroids.10 Our
recruitment of people with asthma buying SABA from
community pharmacies is likely to have recruited peoplewith
more symptomatic and/or more severe asthma, who may be
more likely to engage in regular health review.
In our study, 15% of participants whose lung function was
below 80% predicted, did not use anti-inflammatory asthma
medication, suggesting that additional prescription of anti-
inflammatory asthma medication is probably indicated.
This figure is much less than the report by Kandane-
Rathnayake and colleagues which showed that while 55%
of patients using SABA owned an asthma preventer, only
26% of this middle-aged cohort appeared to be taking it
adequately as judged by a symptom-based severity score.24
Comparable statistics suggesting low use of asthma
preventer medications have been found in surveys based on
asthma symptoms in Australia and in Europe.9,10
In Australia low income groups such as pensioners qualify
for a Health Care Card which provides a greater subsidy for
prescribed medication. This provides a financial incentive
to purchase medication with a doctor’s prescription for
those of lower income, a group known to be at greater risk
of poor asthma outcomes.25 Despite this, those with
a Health Care Card had significantly worse asthma control
than those without a card, suggesting that this policy doesnot completely protect lower-income groups with asthma
from the adverse health effects of their socio-economic
status.
There are several limitations of this study. The study was
designed with asthma control scores as the primary
outcome. The lack of any association between purchasing
SABA without a prescription and asthma control is unlikely
to be due to lack of statistical power as the minimum
important clinical difference of 0.5 lies well outside the
95% confidence interval for the relevant coefficient in the
regression model (Table 3). However it is possible that type
II statistical errors have occurred for some secondary
outcome variables. Further research, including the use of
qualitative methods could expand on our findings.
Our method of recruitment of people with asthma at the
‘point of sale’ of SABA was an efficient method that reliably
allowed us to address differences in self reported asthma
control and lung function according to whether SABAs were
bought with or without a prescription. In recruiting the
intended sample with current asthma, we were also more
likely to have recruited those with poorer asthma control
and/or more severe asthma. Regulations that limit the
purchase of SABA asthma medications without a doctor’s
prescription to those with a previous diagnosis of asthma
would also exclude those with milder or unrecognised
disease. While we recruited participants from randomly
selected pharmacies, the findings should not be generalised
to remote rural settings. They also do not account for
seasonal variability. Our findings must also be interpreted
with some caution in those countries with different access
to health care and different funding of health care services.
Critically, our findings should not be interpreted that
people should not attend doctors for asthma care. Our
study revealed that 15% (47) of participants in our study had
lung function below 80% predicted and yet did not own an
asthma preventer, suggesting that this group in particular
would benefit from medical care. Our findings should be
used to support recommendations from pharmacists to
patients purchasing over-the-counter SABA that they
attend a physician for preventer care. This should espe-
cially be the case if purchase of SABA is frequent.
Conclusions
In summary, this study indicates that the Australian policy
of the provision of SABA without a doctor’s prescription is
not associated with worse asthma control in those
attending pharmacies for purchase of asthma medications.
This is consistent with the opinion that ready access to
SABA medication may even be beneficial to those with
asthma because of improved convenience and accessibility.
However as many as 15% of people attending pharmacies
for SABA may benefit from additional asthma preventer
medication, which reinforces the role of pharmacies as
a site for delivering interventions to improve health
outcomes in people with asthma.
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